ЭФФЕКТИВНОСТЬ РАМИПРИЛА В ЛЕЧЕНИИ И ПРОФИЛАКТИКЕ НЕФРОПАТИИ У БОЛЬНЫХ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ
- Авторы: Минушкина Л.О1
-
Учреждения:
- Учебно-научный медицинский центр УД Президента РФ, Москва
- Выпуск: № 6 (2013)
- Страницы: 105-110
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/280666
- ID: 280666
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Статья посвящена проблемам лечения и профилактики нефропатии у больных артериальной гипертензией (АГ). Рассмотрены вопросы патогенеза гипертонического нефроангиосклероза, значения активации ангиотензин-альдостероновой системы в ее развитии и прогрессировании. Приведены общие принципы использования данной категорией больных препаратов группы ингибиторов ангиотензинпревращающего фермента. Подробно рассмотрены исследования, касающиеся одного из препаратов данной группы - рамиприла. Описаны особенности фармакокинетики и фармакодинамики этого препарата. Подробно приведены результаты исследований, доказывающих эффективность рамиприла в лечении нефропатии у разных категорий больных
Полный текст
Об авторах
Л. О Минушкина
Учебно-научный медицинский центр УД Президента РФ, Москвад.м.н., профессор
Список литературы
- Pontremoli R, Leoncini G, Ravera M, et al. Microalbuminuria, Cardiovascular, and Renal Risk in Primary Hypertension. J Am Soc Nephrol 2002, 13:169-72.
- Yuyun Mf, Khaw KT, Luben R, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study International J of Epidemiol 2004;33(1):189-98.
- Lydakis C, Lip GY. Microalbuminuria and cardiovascular risk. QJM 1998;91(6):381-91.
- Mann JF, Gerstein HC, Dulau-Florea I, et al. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int 2003;84(Suppl.): 192-96.
- Luke RG, Curtis JJ. Nephrosclerosis. In: Schrier RW and Gottschalk CW eds. Diseases of the Kidney. Fifth Edition, Vol. II. Boston. Little Brown and Co 1993:1433-50.
- Batuman V. Lead nephropathy, gout and hypertension. Am J MedSci 1993;305:241-47.
- Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65(3):1009-16.
- Kaplan NM. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996;18(4):658-70.
- Dagenais GR, Yusuf S, Bourassa MG, et al. Effects of ramipril on coronary events in highrisk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104(5):522-26.
- Heinig RE. What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. Diabetes Obes Metab 2002;4(Suppl. 1):19-25.
- Mann JF, Gerstein HC, Yi QL. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol. 2003;14(3):641-47.
- Mann JF, Yi QL, Sleight P, Dagenais GR, et al. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. Clin Nephrol 2005;63(3):181-87.
- Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352(9136):1252-56.
- Ruggenenti P, Perna A, Gherardi G, et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35(6):1155-65.
- Ruggenenti P, Perna A, Remuzzi G; et al. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001;12(12):2832-37.
- Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365(9463):939-46.
- Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albu min: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328(7438):495.
- O'Hare JP, Bilous R, Mitchell T, et al. Low-Dose Ramipril Reduces Microalbuminuria in Type 1 Diabetic Patients Without Hypertension. Diabetes Care 2000;23:1823-29.
- Janickova ZD, Zavadova E, Kvapil M. The Effect of Ramipril Therapy on Cytokines and Parameters of Incipient Diabetic Nephropathy in Patients with Type 1 Diabetes. Mellitus. J of International Medical Research 2007; 35:374-83.
- Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421-31.
- Li PK, Chow KM, Wong TY, et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003;139(2):105-12.
- Pisoni R, Ruggenenti P, Sangalli F, et al. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int 2002;62(3):1010-19.
- Ulusoy S, Ozkan G, Orem C, et al. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Ren Fail 2010;32(8):913-17.
- Gamboa JL, Pretorius M, Todd-Tzanetos DR, et al. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol 2012;23(2):334-42.
- Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16(2):474-81.
- Wuhl E, Trivelli A, Picca S, et al. ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009;361(17):1639-50.
- Wuhl E, Mehls O, Schaefer F. ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 2004;66(2):768-76.
Дополнительные файлы
